Bottom line
PRHSX vs GGHCX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 59% by weight.
But PRHSX is far broader, holding 279 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
PRHSX is cheaper at 0.83% vs 1.07% — a difference of $24 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
PRHSX vs GGHCX side by side
| PRHSX | GGHCX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 1.07% |
| Annual cost per $10k | $83 | $107 |
| 10-yr cost on $10k (prospectus) | $1,025 | $1,784 |
| Max front load | — | 5.5% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +17.7% | +9.2% |
| 5-yr return (annualized) | +4.2% | +2.6% |
| 10-yr return (annualized) | +9.1% | +5.8% |
| Best quarter | +23.5% | +19.6% |
| Worst quarter | −15.8% | −16.5% |
| Net assets (fund) | $11.9B | $1.2B |
| Number of holdings | 279 | 82 |
| Portfolio turnover | 62% | 59% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | GGHCX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +15.5% | +2.2% |
| 2024 | +1.8% | +4.0% | −2.2% |
| 2023 | +3.1% | +3.1% | +0.0% |
| 2022 | −12.2% | −13.5% | +1.3% |
| 2021 | +13.3% | +12.2% | +1.1% |
| 2020 | +30.1% | +14.5% | +15.7% |
| 2019 | +29.1% | +32.0% | −2.9% |
| 2018 | +1.2% | +0.5% | +0.8% |
| 2017 | +28.0% | +15.5% | +12.5% |
| 2016 | −10.4% | −11.7% | +1.4% |
Source: Fund prospectus bar charts
Holdings overlap
12 of PRHSX's top 25 holdings also appear in GGHCX's top 25.
| Holding | PRHSX | GGHCX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 10.59% |
| Johnson & Johnson | 6.63% | 6.76% |
| Unitedhealth Group Inc | 5.99% | 6.17% |
| Abbvie Inc | 5.10% | 4.03% |
| Merck & Co. Inc. | 4.01% | 4.59% |
| Gilead Sciences Inc | 2.82% | 3.63% |
| Thermo Fisher Scientific Inc | 2.52% | 1.55% |
| Vertex Pharmaceuticals Inc | 2.28% | 2.01% |
| Guardant Health Inc | 1.23% | 2.04% |
| Cardinal Health Inc | 1.03% | 2.10% |
| Cvs Health Corp | 0.94% | 2.52% |
| Brightspring Health Services | 0.82% | 2.20% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between PRHSX and GGHCX?
Which is cheaper, PRHSX or GGHCX?
Should I own both PRHSX and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.